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Raltegravir (RAL), a hydroxypyrimidinone carboxamide deriva-
tive, is an integrase strand-transfer inhibitor (INSTI) used in the
treatment and management of human immunodeﬁciency virus
(HIV) infection [1]. It was ﬁrst approved by USFDA in 2007 forr B.V. All rights reserved. This is an open access article under the CC BY-
A. Gupta et al.102the treatment of HIV treatment-experienced patients [2]. RAL is
considered as the ﬁrst generation INSTI that has demonstrated
considerable efﬁcacy in the treatment of naive as well as HIV
treatment-experienced adult patients with viral resistance. It
inhibits the catalytic activity of HIV-1 integrase enzyme, which
is responsible for viral replication by blocking the viral DNA into
the cellular genome by binding to the integrase-viral DNA
complex [3–5]. RAL is approximately 83% plasma bound and
gets rapidly absorbed from the gastrointestinal tract, with peak
plasma concentration achieved within 0.5–1.3 h. It undergoes
hepatic metabolism mainly by uridine diphosphate glucuronosyl-
tranferase enzyme to give an inactive glucuronide metabolite, with
only 9% of the administered dose excreted unchanged in the urine
[6]. Further, the pharmacokinetics of RAL showed important inter-
or intra-subject variability [7].
Selective and sensitive determination of anti-HIVs in plasma is
essential for studying drug–drug interaction, pharmacokinetics,
pharmacodynamics and therapeutic drug monitoring. Several meth-
ods are reported for the determination of RAL as a single analyte
[8–20] or in combination with its glucuronide (Glu) metabolite [21]
or other anti-HIV drugs [22–26] in different biological samples such
as human cell extracts [15,19], cerebrospinal ﬂuid [16], cervicova-
ginal ﬂuid [17], dried blood spots [15], bile [9], feces [9] and human
plasma [8,10–14,18,20–26]. Mainly, liquid chromatography with
UV [10,17,23], photodiode array [18,22], ﬂuorescence [11] or mass
spectrometry [8,9,12–16,19–21,24–26] detection has been used for
the quantiﬁcation of RAL in these matrices.
All reported methodologies using LC–MS/MS quantiﬁed RAL
in the positive ionization mode and few discussed in-source
conversion of RAL-Glu to RAL [14,15,21,24] and its possible
interference in the quantiﬁcation of RAL. Thus, it is essential to
develop an adequately sensitive, rapid and selective method, with
chromatographic resolution of interfering compounds like RAL-
Glu to avoid overestimation of RAL concentration. In the present
work, negative ionization mode was selected as it showed better
selectivity without compromising the sensitivity of the method.
Further, the chromatographic conditions were suitably optimized
on a Chromolith RP-18e endcapped C18 column under isocratic
elution for baseline separation of RAL from RAL-Glu. The
method described was used to support a bioequivalence study in
healthy Indian subjects.2. Experimental
2.1. Chemicals and materials
Reference standard of raltegravir (98.5%) was procured from Hetero
Drugs Limited (Hyderabad, India). Raltegravir-d3 (IS, 98%) and
raltegravir glucuronide were procured from Toronto Research Chemi-
cals Inc. (Ontario, Canada). HPLC grade methanol, acetonitrile,
ammonium formate, dichloromethane (DCM), n-hexane and formic
acid were obtained from Merck Specialties Pvt. Ltd. (Mumbai, India).
Water used in the entire analysis was prepared from Milli-Q water
puriﬁcation system procured from Millipore (Bangalore, India). Blank
human plasma was obtained from Supratech Micropath (Ahmedabad,
India) and was stored at 20 1C until use.
2.2. Liquid chromatographic and mass spectrometric conditions
An LC-VP HPLC system (Shimadzu, Kyoto, Japan) was used for
chromatographic separation of RAL and IS on Chromolith RP-18eendcapped C18 (100 mm 4.6 mm) analytical column having
monolithic silica rod (Phenomenex, Hyderabad, India) maintained
at 40 1C in the column oven. For isocratic elution, the mobile
phase consisting of 10 mM ammonium formate in water, pH 3.0,
and acetonitrile (30:70, v/v) was delivered at a ﬂow-rate of
1.2 mL/min. The total eluate from the column was split in 85:15
(v/v) ratio; ﬂow directed to the electrospray interface was
equivalent to 180 μL/min. The autosampler temperature was
maintained at 5 1C and the average pressure of the system was
1200 psi. A triple quadrupole mass spectrometer API-4000 (AB/
MDS SCIEX, Toronto, Canada) equipped with electrospray
ionization and operating in negative ionization mode was used
for detection of RAL and IS. For quantitation, multiple reaction
monitoring (MRM) was used to monitor precursor-product ion
transitions at m/z 443.1-316.1 for RAL and m/z 446.1-319.0
for IS. The nebulizer gas, heater gas, ion spray voltage, heater
temperature, curtain gas nitrogen and collisional activation dis-
sociation were optimized at 50 psig, 60 psig, 4500 V, 300 1C,
35 psig and 7 psig, respectively. The compound-dependent para-
meters like declustering potential, entrance potential, collision
energy and collision cell exit potential were maintained at
40.0 V, 10.0 V, 27.0 eV and 7.0 V, respectively. A dwell
time of 100 ms was set for both the compounds. Data collection,
peak integration, and calculations were performed using Analyst
software version 1.4.2.
2.3. Preparation of standard solutions and quality control
samples
The standard stock solution of RAL (1000 mg/mL) was prepared
by dissolving its accurately weighed amount in methanol. Its
working solution was prepared by appropriate dilution of stock
solution in methanol:water (50:50, v/v). Calibration standards
(CSs) and quality control (QC) samples were prepared by
spiking blank plasma with standard spiking solutions. CSs were
prepared at 2.0, 4.0, 12.0, 45.0, 90, 180, 480, 1200, 3000 and
6000 ng/mL concentrations while QC samples were prepared at
5000 ng/mL (HQC, high quality control), 2500 ng/mL (MQC,
medium quality control), 6.0 ng/mL (LQC, low quality control)
and 2.0 ng/mL (LLOQ QC, lower limit of quantiﬁcation quality
control) concentrations. Stock solution (1000 mg/mL) of the IS
was prepared by dissolving 2.0 mg of RAL-d3 in 2.0 mL of
methanol. An aliquot of 10 mL of this solution was further
diluted to 25.0 mL in the same diluent to obtain a solution of
400 ng/mL. Standard stock and working solutions used for
spiking were stored at 5 1C, while CSs and QC samples in
plasma were kept at 70 1C until use.
2.4. Sample preparation
Prior to analysis, all frozen subject samples, CSs and QC samples
were thawed and allowed to equilibrate at room temperature. To an
aliquot of 100 mL of spiked plasma/subject sample, 50 mL of IS
was added and vortexed for 20 s. Thereafter, 50 mL of 0.1% formic
acid in water was added and vortexed for another 20 s. Extraction
of samples was carried out with 2.5 mL of DCM and n-hexane
(50:50, v/v) on a rotospin for 10 min at 32g. The samples were
then centrifuged at 3204g for 5 min at 10 1C. After centrifugation,
2.0 mL of the supernatant organic layer was transferred to an
evaporation tube. The supernatant was evaporated to dryness in a
thermostatically controlled water-bath maintained at 40 1C under a
LC–MS/MS determination of raltegravir in human plasma 103stream of nitrogen. The dried residue was reconstituted in 150 mL
of mobile phase [10 mM ammonium formate in water, pH 3.0 and
acetonitrile (30:70, v/v)] and 10 mL was used for injection in the
chromatographic system.
2.5. Validation of assay
The bioanalytical method was validated as per the USFDA
guidelines [27] and was similar to the one described in our
previous reports [28,29]. System suitability test was performed by
injecting six successive injections using an aqueous standard
mixture of RAL (2500 ng/mL) and IS (400 ng/mL) at the start
of each batch. System performance was checked by injecting one
extracted LLOQ sample with IS at the beginning of each analytical
batch. Carryover effect of autosampler was veriﬁed by sequentially
injecting extracted blank plasma-ULOQ sample-extracted
blank plasma-LLOQ sample.
The selectivity of the method for endogenous plasma matrix
components was evaluated in ten different batches of blank plasma
(7 normal K3EDTA plasma and 1 each of lipemic, haemolysed and
heparinised plasma). Additionally, lipemic and hemolytic effects of
plasma were assessed at HQC and LQC levels in six replicates. These
sets were processed along with freshly prepared CSs and qualifying
QC samples in duplicate using normal plasma lots. As per the
acceptance criteria, the accuracy of lipemic and hemolytic samples
should be within 85–115%. The selectivity of the method towards
commonly used medications by human volunteers was checked for
acetaminophene, cetirizine, domperidone, ranitidine, diclofenac, ibu-
profen, nicotine and caffeine in six different batches of human plasma
containing K3EDTA as an anticoagulant. Their stock solutions were
prepared by dissolving requisite amount in methanol and water
(50:50, v/v). Further, a mixed working solution of acetaminophen
(1000 mg/mL), cetirizine (20 mg/mL), domperidone (1 mg/mL), raniti-
dine (27.5 mg/mL), diclofenac (100 mg/mL), ibuprofen (2250 mg/mL),
nicotine (5 mg/mL) and caffeine (1000 mg/mL) was prepared in the
same diluents, spiked in plasma and analyzed under the same
conditions at LQC and HQC levels in six replicates. These sets were
processed along with freshly prepared CSs and qualifying QC
samples in duplicate. As per the acceptance criteria, the accuracy
should be within 85–115%.
The linearity of the method was determined by analysis of ﬁve
calibration curves containing 10 non-zero concentrations. The area
ratio response for the analyte/IS obtained from MRM was used for
regression analysis. The calibration curves were analyzed indivi-
dually by using least square weighted (1/x2) linear regression. The
lowest standard on the calibration curve was accepted as the
LLOQ, if the analyte response was at least ten times more than that
of drug-free (blank) extracted plasma.
Intra-batch accuracy and precision for RAL were determined
by analyzing six replicates of QC samples along with calibra-
tion curve standards on the same day. The inter-batch accuracy
and precision were assessed by analyzing ﬁve precision and
accuracy batches on three consecutive days. Sample injection
reproducibility was also checked by re-injecting one entire
validation batch.
Assessment of ion suppression/enhancement was ascertained
through post-column analyte infusion. In this experiment, a standard
solution containing RAL (2500 ng/mL) was infused post-column via a
‘T’ connector into the mobile phase at 10.0 mL/min, employing an
infusion pump. Thereafter, aliquots of 10 mL of extracted control
(blank) plasma were injected into the column and MRM chromato-
grams were acquired for RAL and IS.The extraction recovery of RAL and IS was estimated by
comparing the mean area response of samples spiked before
extraction to that of extracts with post-spiked samples (spiked
after extraction) at three QC levels. Matrix effect, expressed as
matrix factors (MFs), was assessed by comparing the mean area
response of post-extraction fortiﬁed samples with mean area of
solutions prepared in mobile phase solutions (neat standards).
IS-normalized MFs (RAL/IS) were calculated to access the variability
of the assay due to matrix effects. Relative matrix effect was assessed
from the precision (%CV) values of the slopes of the calibration
curves prepared from ten different plasma lots/sources.
The standard stock solutions of RAL and IS were evaluated for
short-term and long-term stability at 25 and 5 1C, respectively. The
analyte stability in the spiked plasma samples was evaluated by
measuring the area ratio response (RAL/IS) of stability samples
against freshly prepared standards having identical concentration.
Bench-top (at room temperature), processed sample stability at
room temperature and at refrigerated temperature (5 1C), dry
extract (20 1C), freeze–thaw (20 and 70 1C) and long term
(20 and 70 1C) stability of RAL in plasma were studied at
LQC and HQC levels.
Method ruggedness study was done with two precision and
accuracy batches. The ﬁrst batch was analyzed by a different
analyst while the second batch was studied on two different columns of
the same make having different batch numbers. Dilution integrity
experiment was evaluated by preparing the spiked standard at
30,000 and 8000 ng/mL concentrations for 1/10 and 1/2 dilutions
in the screened plasma. The precision and accuracy for dilution
integrity standards at 1/10 (3000 ng/mL) and 1/2 (4000 ng/mL)
dilution were determined by analyzing the samples against freshly
prepared calibration standards.
2.6. Application of the method and incurred sample reanalysis
(ISR)
The validated method was applied to quantify plasma RAL
concentration for a bioequivalence study in 18 healthy Indian
subjects after oral administration of test (400 mg tablets) and a
reference (ISENTRESSs, 400 mg raltegravir tablets from Merck &
Co., Inc. Whitehouse Station, NJ 08889, USA) formulation under
fasting conditions. Written consent was taken from all the subjects
after informing them about the objectives and possible risks involved in
the study. The study was conducted as per the International Con-
ference on Harmonization, E6 Good Clinical Practice guidelines
[30]. Blood samples were collected at 0.0 (pre-dose), 0.33, 0.67,
1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00,
4.50, 5.00, 6.00, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0 and 36.0 h after
oral administration of test and reference formulations in labeled
K3EDTA-vacutainers. Plasma was separated through centrifuga-
tion and kept frozen at 70 1C until analysis.
An incurred sample reanalysis was also done by reanalysis of 87
subject samples (10% of total subject samples analyzed) [31]. The
selection criterion was based on samples which were near the Cmax
and the elimination phase in the pharmacokinetic proﬁle of the drug.3. Results and discussion
3.1. LC–MS/MS method development
All the reported methods employed positive ionization mode for
LC–MS/MS analysis of RAL in different biological matrices
A. Gupta et al.104[8,9,12,14–16,19–21,24–26]. Contrary to this approach, negative
ionization mode was selected in the present work as it showed
better selectivity without compromising the sensitivity. Further-
more, the response obtained during initial trials with both the
polarities was comparable. The intensities of the most stable
daughter ions were 4.97e5 cps (443.1-316.1) and 5.01e5 cps
(445.1-109.0) in the negative and positive ionization modes,
respectively, under the optimized conditions. The same approach
was adopted by Djerada et al. [25] for efavirenz, a non-nucleoside
reverse transcriptase inhibitor, using UPLC–MS/MS technology.
The ESI conditions were optimized so as to have predominant
deprotonated precursor [M-H] ions at m/z 443.1 for RAL and m/z
446.1 for IS in the Q1 MS full scan spectra. In the product ion
mass spectrum, the most consistent and intense fragments were
observed at m/z 316.1 and 319.0 for RAL and IS, respectively, by
applying –27 eV collision energy. These fragments were formed
from the deprotonated parent ion by cleavage of oxadiazole moiety
containing the amide functionality as shown in Fig. 1. A dwellFig. 1 Product ion mass spectra of (A) raltegravir (m/z 443.1-316.1, sc
446.1-319.0, scan range 100–500 amu), in the negative ionization mode
Fig. 2 MRM chromatograms of (A) a mixture of raltegravir atime of 100 ms for both the compounds was adequate to obtain
sufﬁcient data points for quantiﬁcation.
Although there are several methods for the quantiﬁcation of
RAL, few studies reported the presence of RAL-Glu metabolite
in subject samples [14,15,21,24]. Ter Heine et al. [15] reported
a secondary peak corresponding to RAL-Glu in a patient sample
which overlapped with the peak of RAL in the positive
ionization mode. This was due to the in-source fragmentation
of RAL-Glu and its presence was conﬁrmed by lowering the
declustering potential. However, as it was difﬁcult to comple-
tely eliminate this interference by changing the mass para-
meters, it was chromatographically separated by changing the
elution conditions from isocratic to gradient mode. Similarly,
Fayet et al. [24] veriﬁed the presence of RAL-Glu in a patient
sample (collected at 1.5 h after oral administration of 400 mg
RAL) separately by single ion monitoring at m/z 619 corre-
sponding to this metabolite in the negative ionization mode. In
another report [14], the presence of this secondary peak wasan range 100–500 amu) and (B) internal standard, raltegravir-d3 (m/z
.
nd raltegravir glucuronide and (B) raltegravir glucuronide.
Fig. 3 MRM ion-chromatograms of (A) double blank plasma (without analyte and IS), (B) blank plasma with raltegravir-d3 (IS), (C) raltegravir
at LLOQ and IS and (D) subject sample at Cmax after administration of 400 mg dose of raltegravir.
LC–MS/MS determination of raltegravir in human plasma 105completely eliminated by pre-treatment of patient samples with β-
glucuronidase, which effectively broke the bond between RAL and
glucuronic acid and released free RAL. Interestingly, all the
methodologies employing protein precipitation (PP) for sample
preparation reported the presence of RAL-Glu metabolite in subjectsamples [14,15,21,24]. Thus, gradient elution conditions were imple-
mented for chromatographic separation of the drug and its metabolite.
However, in the present work, chromatographic conditions were
optimized to have baseline separation of RAL and RAL-Glu under
isocratic elution.
Table 1 Intra- and inter-batch precision and accuracy for raltegravir.
QC samples (ng/mL) Intra-batch (n¼6; single batch) Inter-batch (n¼30, 6 from each batch)
Mean conc. found (ng/mL) CV (%) Accuracy (%) Mean conc. found (ng/mL) CV (%) Accuracy (%)
HQC (5000) 4915.7 2.77 98.3 4815.7 0.87 96.3
MQC (2500) 2483.7 2.98 99.4 2485.4 1.43 99.4
LQC (6.0) 6.12 2.92 102.1 6.13 2.38 102.2
LLOQ QC (2.0) 2.08 3.64 103.9 2.04 2.53 102.1
Table 2 Extraction recovery and matrix factors for raltegravir and raltegravir-d3.
QC level
(ng/mL)
Area response (n¼6) Extraction recovery
(A/B 100) (Internal standard)
Matrix factor
A (CV, %) B (CV, %) C (CV, %) Analyte
(B/C)
IS IS-
normalized
LQC (6.0) 3974 (2.8) 4220 (4.7) 4241 (3.4) 94.2 (92.6) 0.995 1.003 0.992
MQC (2500) 1,551,632 (5.8) 1,701,708 (6.6) 1,723,059 (6.2) 91.2 (91.8) 0.987 0.998 0.988
HQC (5000) 3,321,302 (4.7) 3,590,736 (5.6) 3,596,711 (5.0) 92.5 (91.1) 0.998 0.999 0.999
A: mean area response of samples prepared by spiking in extracted blank plasma.
B: mean area response of samples prepared by spiking before extraction.
C: mean area response of samples prepared by spiking in mobile phase (neat samples).
Table 3 Relative matrix effect in eight different plasma lots
for raltegravir.
Plasma lot Slope
Lot-1 (K3EDTA) 0.00245
Lot-2 (K3EDTA) 0.00238
Lot-3 (K3EDTA) 0.00238
Lot-4 (K3EDTA) 0.00249
Lot-5 (K3EDTA) 0.00236
Lot-6 (K3EDTA) 0.00233
Lot-7 (K3EDTA) 0.00235
Lot-8 (heparinized) 0.00254
Lot-9 (haemolysed) 0.00243
Lot-10 (lipemic) 0.00249
Mean 0.00242
Standard deviation 0.000067
Coefﬁcient of variation (%) 2.77
A. Gupta et al.106For this experiment, during method development a mixture of
RAL (50 ng/mL) and RAL-Glu (15 ng/mL) was chromatographed
for baseline separation on different reversed-phase columns like
Gemini C18 (50/150 mm 4.6 mm, 5.0 mm), ACE C18
(150 mm 4.6 mm, 5.0 mm), Cosmosil C18 (150 mm 4.6 mm,
5.0 mm), Symmetry C18 (150 mm 4.6 mm, 5.0 mm) and Chro-
molith RP-18e endcapped C18 (100 mm 4.6 mm) using formic
acid/ammonium formate together with methanol/acetonitrile in
different compositions. All the columns provided adequate
response. However, on Gemini C18, the analytes and IS had
limited retention (RT0.5 min), while the peak shape was
unacceptable on ACE C18 and Cosmosil C18 columns at a ﬂow
rate ranging from 0.6 to 1.0 mL/min. Symmetry C18 provided
adequate response as well as peak shape but the retention time for
the analytes was above 4.0 min. Thus, these columns were not
considered for further experiment. The best chromatographicconditions were achieved on Chromolith RP-18e column with
adequate response, symmetrical peak shape, baseline separation
within 2.0 min at a ﬂow rate of 1.2 mL/min (Fig. 2). This column
provides high efﬁciency and an improved performance due to the
fast mass transfer kinetics and high binding capacity of monolithic
silica compared to particle packed columns. These conditions can
serve well for reliable quantiﬁcation of RAL even in the presence of
RAL-Glu, which was not quantiﬁed as it is pharmacologically inactive.
Further, the method selectivity was evident from the MRM
chromatograms of double blank plasma, plasma spiked with IS and
an LLOQ sample as shown in Fig. 3. There was no interference due
to endogenous plasma components at the retention time of RAL and
IS. Additionally, all eight commonly used medications studied in
this work did not interfere with the quantitation of RAL due to their
different MRM transitions. Unlike previous reports [14,15,21,24],
there was no peak corresponding to RAL-Glu in healthy Indian
subject samples under investigation. Chromatogram in Fig. 3 shows
complete absence of this circulating metabolite in plasma samples
even up to 4 h after oral administration of the drug.
Several assays [8,11–13,18] have employed liquid–liquid
extraction (LLE) with n-hexane–DCM (50:50, v/v) in the presence
of ammonium acetate buffer (pH 4.0) prior to extraction. In the
present work, 0.1% formic acid was used to break high drug–
protein binding and render the analyte in an unionized state.
Further, reconstitution with the mobile phase afforded better peak
shape and overall chromatographic performance with quantitative
and precise recovery for RAL (91.2–94.2%) across QC levels.
3.2. Assay validation results
The precision values for system suitability ranged from 0.03% to
0.11% for the retention time and 0.48–1.32% for the area ratio
response of RAL/IS. For system performance, the S/N ratio at
LLOQ was Z40. The evaluation of autosampler carry-over was
performed in each analytical run so as to ensure that it does not
Fig. 4 Injection of four extracted blank plasma samples during post-column infusion of raltegravir with a chromatogram of raltegravir at
HQC level.
Table 4 Stability of raltegravir in plasma under various conditions (n¼6).
Storage conditions Nominal concentration
(ng/mL)
Mean stability sample
(ng/mL)7SD
Change (%)
Bench-top stability at room temperature (25 1C) for 8 h 5000 4709.67772.69 5.81
6.0 6.4370.15 7.17
Freeze-thaw stability after 5th cycle at 20 1C 5000 4773.507106.40 4.54
6.0 6.1770.22 2.83
Freeze-thaw stability after 5th cycle at 70 1C 5000 4804.837218.23 3.90
6.0 6.1770.24 2.83
Wet extract (autosampler) stability at 4 1C for 65 h 5000 4838.177209.68 3.24
6.0 6.2470.28 4.00
Wet extract stability at 25 1C for 4 h 5000 4959.337287.84 0.81
6.0 6.2370.25 3.83
Dry extract stability in deep freezer at 20 1C for 65 h 5000 4874.007183.04 2.52
6.0 6.2370.25 3.83
Long-term stability at 20 1C for 42 days 5000 4844.007247.40 3.12
6.0 5.9470.26 1.00
Long-term stability at 70 1C for 42 days 5000 4861.507315.59 2.77
6.0 6.2070.23 3.33
Change ð%Þ ¼ Mean stability sample–Mean comparison samplesMean comparison samples  100
Fig. 5 Mean plasma concentration-time proﬁle of raltegravir after
oral administration of 400 mg (test and reference) tablet formulation to
18 healthy Indian subjects.
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There was practically negligible carry-over (r0.003%) during
carry-over experiment in the extracted blank plasma (without IS
and analyte) after subsequent injection of highest CS at the
retention time of RAL and IS as shown in Supplementary Fig. 1.
The calibration curves showed good linearity over the estab-
lished concentration range of 2.0–6000 ng/mL (r2Z0.9978) forRAL. The mean linear equation for calibration curves was y¼
(0.0024270.00021)xþ(0.006170.0022), where y is the peak area
ratio of the RAL/IS and x is the concentration of RAL.
The accuracy and precision (%CV) observed for the CSs ranged
from 93.1% to 104.0% and 1.6% to 3.5%, respectively, for RAL.
The intra-batch precision (%CV) ranged from 2.77% to 3.64% and
the accuracy was within 98.3–103.9% for RAL. Similarly, for
inter-batch experiments, the precision varied from 0.87% to 2.53%
and the accuracy was within 96.3–102.2% (Table 1).
The mean extraction recovery and IS-normalized MFs for RAL
are shown in Table 2. The recovery obtained was consistent,
ranging from 91.2% to 94.2% across three QC levels. As co-
eluting matrix components can directly impact the overall relia-
bility of a validated method, it is suggested to compute MFs to
assess the matrix effect. The IS-normalized MFs using stable-
isotope labeled IS should be close to unity due to similarities
in the chemical properties and elution behavior of the analyte and
IS. The IS-normalized MFs ranged from 0.992 to 0.999 for RAL.
Additionally, it is required to check the relative matrix effect in
lipemic and haemolysed plasma samples together with normal
K3EDTA plasma. The coefﬁcient of variation (%CV) of the slopes
of calibration lines for relative matrix effect in ten different plasma
Table 5 Salient features of selected liquid chromatographic methods developed for raltegravir as a single analyte in human plasma
with mass spectrometric detection.
Extraction
technique
Sample
volume
(mL)
Linear
range
(ng/mL)
Retention
time (min);
run time (min)
Application Refs.
LLE with
hexane–DCM
200 2.0–1000 1.56; 3.5 To support 18 clinical studies during Phase I through
Phase III
[8]
LLE with
hexane–DCM
200 1.0–3000 3.80; 7.0 Determination of raltegravir in a single HIV-infected patient [12]
LLE with
hexane–DCM
500 10.0–7680 8.23; 16.0 – [13]
PP with
ACN–
methanol
25 10–3000 1.65; 4.0 Analysis of human plasma samples [14]
PP with
ACN–
methanol
50 50–10000 4.20; 10.0 Pharmacokinetic study in one HIV-infected patient [15]
LLE 100 5.0–2560 –; 1.0 Pharmacokinetic study in human plasma samples [20]
PP with ACN 50 2.0–2000
nmol/L
4.90; 9.0 Pharmacokinetic study with 400 mg raltegravir in 6 healthy subjects [21]
LLE with
hexane–DCM
100 2.0–6000 1.35; 2.0 Bioequivalence study with 400 mg raltegravir in 18 healthy
subjects;
Reanalysis of 87 incurred samples (% change within717%)
PW
LLE: liquid–liquid extraction; PP: protein precipitation; SPE: solid phase extraction; DCM: dichloromethane; ACN: acetonitrile; PW:
present work.
A. Gupta et al.108lots was 2.77 (Table 3). Furthermore, the blank extracts obtained
through the LLE procedure were analyzed by the post-column analyte
infusion method. The result conﬁrmed the absence of signal
suppression or enhancement at the retention time of RAL and IS
(Fig. 4).
The stock solutions kept for short-term and long-term stability as
well as spiked plasma samples showed no evidence of degradation
under all the studied conditions. Samples for short-term stability
remained stable up to 8 h, while the stock solutions of RAL and IS
were stable for a minimum period of 18 days at refrigerated
temperature of 5 1C. No signiﬁcant degradation was observed for
the analyte during sample storage and any of the processing steps
during extraction. The detailed results for stability studies are
presented in Table 4. Sample dilution test was performed to ascertain
dilution reliability of samples which were above the ULOQ. The
precision (%CV) values for 2-fold and 10-fold dilution were 1.5%
and 0.4%, while the accuracy results were 96.0% and 102.4%,
respectively. The precision and accuracy for method ruggedness on
two different Chromolith RP-18e columns and with different analysts
were within 0.9–4.2% and 93.5–103.8%, respectively.3.3. Application to a bioequivalence study and ISR results
As yet there are no reports on the pharmacokinetics of RAL in
Indian subjects. Therefore, the method was applied to monitor
RAL concentration in human plasma samples after oral adminis-
tration of a single 400 mg dose of RAL. Fig. 5 shows the mean
plasma concentration vs. time proﬁle for RAL under fasting.
Although the area under the plasma-time curve (AUC) increases
by about 19% with a high fat meal, RAL can be given without regard
to food [1]. The time required to reach peak plasma concentration
was 2 h, which was almost double as observed by Kassahun et al.
[9] with 200 mg dose of RAL in healthy subjects. Nevertheless, theCmax [test: 4642 ng/mL; reference: 4270 ng/mL] and AUC0–36 h
values [test: 10,463 h ng/mL; reference: 9708 h ng/mL] were compar-
able with their work. For studies in healthy subjects, the pharmacoki-
netics of RAL was reported to be dose-dependent for oral doses ranging
from 10 to 1600 mg [9]. Further, the reproducibility of the assay was
studied by reanalysis of 87 incurred samples (Supplementary Fig. 2).
The % change was within717%, which was within the acceptance
criterion of 720% [31].
3.4. Comparison with existing methods
The proposed method is more sensitive compared to several
methods developed for determination of raltegravir in human
plasma [8–11,13–15,18,20,24–26]. Further, it is more rapid than
all other methods except one report [20]. The present method
employs small plasma volume (100 mL) for processing, which is
much less compared to many reported procedures. A detailed
comparison of salient features of different liquid chromatographic
methods with mass spectrometric detection developed for RAL is
given in Table 5.4. Conclusions
The proposed validated LC–MS/MS assay provided a reliable and
rugged approach for the quantitation of RAL in human plasma in
the negative ionization mode. The LLE procedure afforded highly
selective separation of the analytes from endogenous components
enabling quantiﬁcation of 0.01–40 ng on-column per sample
injection employing 100 mL plasma samples. The method was
extensively validated for matrix effect and stability under different
storage conditions. It was successfully applied in a clinical study
and the reproducibility of the assay was demonstrated by incurred
sample reanalysis.
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